Abstract: Re) is a high energy beta-emitting radioisotope of widespread interest for use in nuclear medicine, oncology and other therapeutic applications. High energy beta emission (16.9 hour half-life) with Emax 2.12 MeV and gamma emission at 155 keV (15 % Re generator prototypes.
INTRODUCTION
The history describing the initial discovery of technetium ("masurium") and rhenium in Germany during the 1930's involved the use of minimal technical tools but great effort and impressive technical insight [1] . Rhenium (Re, element 75) was first isolated and identified by German scientists Ida Noddack-Tacke and Walter Noddack while working in Strasbourg, who named this new element after the Roman Latin designation "rhenus" for the river Rhine [1] . Of course during that time investigators had not envisaged the important future applications which technetium-99m ( 99m Tc) and 188 Re would subsequently play for diagnosis and therapy in the future field of nuclear medicine.
Over the last three decades interest in the therapeutic use and development of 188 Re-labeled radiopharmaceuticals has persisted with broad interest on an international basis, and a number of reviews have discussed this progress [2] [3] [4] [5] [6] [7] [8] 188 Re generators has provided NCA 188 Re to pursue new radiolabeling strategies and the development, evaluation and clinical use of a variety of therapeutic radiopharmaceuticals as described in the following paper. Although embedded in the literature and not widely known, early preliminary studies, however had actually described prototype 188 W/ 188 Re generators to obtain 188 Re for the wrong reasons, since 188 Re had been promoted as a diagnostic radioisotope during the period when the 99 Mo/ 99m Tc generator was initially being introduced [9] [10] [11] , apparently without regard to consideration of radiation dose. Initial projected studies with 188 Re available from an early prototype zirconium-based generator had thus been proposed use for imaging [9] , although the gamma decay is accompanied by emission of high energy beta particles. Use of 188 Re for diagnostic applications would of course result in unacceptable radiation dose to both targeted and nontargeted tissues. 188 Re solution for preparation of the 188 W/ 188 Re generators.
The 188 W/ 188 Re "chromatographic-type" generator prototypes (Figure 1) utilize loading of the processed 188 W divalent anion (WO 4 -2 , half-life 69 days) which is obtained by reactor double neutron capture production on enriched 186 W targets [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The irradiated targets are processed and the 188 W tightly bound as tungstic acid to an adsorbant. The 188 Re (half-life 16.9 hours) generated as the perrhenate (ReO 4 -1 ) monovalent anion by beta decay of 188 W is not tightly bound to the adsorbant, and readily removed from the generator by elution, for instance, with physiological saline.
Because of the relative radioactive half-lives, the 188 Re daughter is quickly re-formed by continuous ingrowth from 188 W decay after elution of the bolus from the 188 W/ 188 Re equilibrium mixture (Figure 2 , left panel). On a daily 24 hour elution basis, approximately 62% of the equilibrium yield of 188 Re is eluted, indicating that about 600 mCi can initially be eluted from a 1 Ci 188 W/ 188 Re generator at equilibrium. Data obtained from successive elution of a 1 Ci generator [4] summarized in Figure 2 (right panel) demonstrate the reproducibly high 188 Re yields with low 188 W parent breakthrough for elution over a two month period.
ADVANTAGES OF THERAPEUTIC USE OF RHENIUM-188
The availability of high yield NCA 188 Re, on demand, from the 188 W/ 188 Re radionuclide generator system was a central practical consideration which had stimulated interest in the use of 188 Re for a variety of therapeutic applications, which are discussed in detail in an accompanying paper in this issue of IJNMR. Radiopharmaceutical development beginning in the 1980's has subsequently blossomed into a variety of clinical applications. Figure 3 (left panel) further illustrates the theoretical elution characteristics and multi-cycling of the generator for four elution cycles demonstrating the slow decay of 188 W. The curves for 188 W decay, 188 Re in growth and 62% daily 188 Re elution yields are shown in Figure 3 (right panel). 188 Re generator is the relatively rapid in growth of 188 Re from 188 W decay following elution which provides 62% of the maximal 188 Re in growth available every 24 hours. RightGenerator operational is consistent and predictable over a long time period with high 188 Re yields and low 188 W parent breakthrough.
Figure 3:
In growth curves for 188 Re generated from decay of 188 W. Left -four successive cycles following 24 elution of 188 Re (half-life 16.9 hours) illustrating daily in growth and availability of high daily activity levels of 188 Re. Right -The slow decay of 188 W (69 day half-life) will provide high daily levels of 188 Re. Even after four months (1.7 decay half-lives of 188 W) a 1 Ci generator will decay to only 300 mCi. Although the saline bolus elution volume is essentially the same for the operational shelflife of the generator, post elution concentration can provide constant specific volume (mCi/mL) levels of 188 Re eluted throughout the generator shelf-life. 188 Re generator prototypes have been described in the literature , the alumina-based generator system has been demonstrated as the most simple, reliable and is widely used to obtain 188 Re for clinical use [12, [22] [23] [24] [25] [26] [30] [31] [32] . Other variations which have been described and include 188 W/ 188 Re generators based on zirconium oxide/zirconia [27, [37] [38] [41] [42] , gel-type technology [44] [45] [46] , electrochemistry [43] , extraction centrifuge techniques [40] , thermo-chromatography, use of high capacity adsorbent-based, nanomaterial-based and solvent extraction, but apparently none of these systems have been further evaluated for routine use of 188 Re in a clinical setting. The first evaluation of the generator separation of no-carrier-added 188 Re from the 188 W parent using a generator-based system was explored in 1966 [9] [10] . This system involved use of 188 W bound to the zirconium oxide adsorbant eluted with the methyl ethyl ketone (MEK) organic solvent. Apparently not further evaluated, this system was impractical for providing 188 Re for clinical evaluation of 188 Re-based therapeutic agents and further development and use did not mature. This approach was impractical, since eluant evaporation, subsequent manipulation and re-dissolution of 188 Re in a system to allow labeling of the desired targeting agent presented technical and quality control challenges.
In addition to the alumina-based systems, one area of 188 W/ 188 Re generator development which had been of extensive earlier interest involved the use of "gels," which consist of homogeneous admixture of 188 
IMPORTANCE OF AVAILABILITY OF TUNGSTEN-188
In contrast to the availability of very high specific activity microscopic levels of 99 Mo produced at about 6% yield via nuclear fission of uranium-235 ( 188 Re eluants.
AVAILABILITY OF TUNGSTEN-188 AND W-188/RE-188 GENERATORS
For the expanded clinical utilization of 188 Re a crucial issue which must be addressed is the dependable, routine availability of GMP-produced 188 W/ 188 Re generators. Re generators are available in high activity levels from the three manufacturers described in Table 1 . Although these three prototypes are manufactured under quality conditions, only the Rhein Eo generator equipped with the post elution 188 Re concentration cassettes from IRE-Elit in Belgium, is W from the Dimitrovgrad facility and the less than expected modest generator sales are factors which resulted in removal of this generator from the POLATOM product line.
Although availability of high specific activity 188 Re from the 188 W/ 188 Re generator is the preferred costeffective route, it is surprising that the well-established "direct" reactor production and facile post irradiation processing and dispensing of high specific activity 188 Re by irradiation of enriched 187 Re [ 187 Re (n,γ) 188 Re] (Figure 1) has not been pursued for availability of this therapeutic radionuclide for radiopharmaceutical preparation for clinical applications. There are many research reactors throughout the world, including many developing countries, which have sufficient thermal neutron flux for production of 188 Re with sufficient specific activity by this route. Target preparation, processing and 188 Re product dispensing are straight forward and the 16.9 hour half-life of 188 Re would allow delivery even beyond local sites. All of the aluminabased generators summarized in Table 1 have been reported -primarily in promotional product information available on the Internet -to have predictable operation with "long" useful shelf-lives to provide 188 Re in about 95% yield and with low 188 W breakthrough values of < 10 -3 %/ 188 Re bolus. 188 Re specific volume is a key issue -and much shorter than the demonstrated prolonged time period for generator performance of several months, unless post elution 188 Re bolus concentration methods are used. Important technologies which make routine availability of 188 Re possible include GMP generator production, automated systems for generator elution and 188 Re bolus concentration, effective chemical strategies for attachment of 188 Re to targeting molecules and the increasing availability of radiolabeling "kits" for radiopharmacy preparation of targeted 188 Re radiopharmaceuticals. Obviously, in addition to GMP manufacture of the 188 W/ 188 Re generators, the same quality programs are required for production of the concentration units and "kits" which would result in significantly higher costs to the expanded clinical introduction of specific 188 Re-labeled therapeutic agents.
ISSUES ASSOCIATED WITH AVAILABILITY AND UTILIZATION OF THE W-188/RE-188 GENERATOR IN THE RADIOPHARMACY

Post Elution Rhenium-188 Bolus Concentration Using Tandem Cation/Anion Columns
Although apparently only one commercially available 188 W/ 188 Re generators apparently is provided with post elution concentration units/cassettes ( Table 1 ; IRE-Elit) to obtain 188 Re of sufficient specific volume for radiopharmaceutical radiolabeling, the use of such technologies is widely felt to be very effective in considerably extending the generator shelf-life and to reduce unit 188 Re dose costs [50] . These systems are readily prepared, easy to use and are very efficient and effective in concentrating 188 Re eluants when a higher specific volume is required (Figure 4) . Our ORNL technology using a tandem silver nitrate/QMA system had first been reported [4, [50] [51] [52] [53] [54] [55] [56] [57] for isolation of the 188 Re-perrhenate anion from the high volume generator eluant. Several alternate post elution approaches/ systems had subsequently been reported in the literature using various perrhenate trapping cartridge systems [58] [59] [60] [61] [62] [63] , but it is unclear, however, which of these systems have been routinely used for clinical application. Use of the tandem silver impregnated chloride trapping/perrhenate trapping column system represents effective access to high specific volume 188 Re solutions which has been used for a number of years to obtain high specific volume 188 Re for a variety of clinical applications, including single center and IAEA-sponsored programs for vascular therapy describe here later, and for liver cancer therapy. Use of such disposable 188 Re bolus concentration cartridge units using readily available and inexpensive components is well described [4, [53] [54] [55] [56] [57] , is well established and disposable 188 Re bolus concentration systems can be provided as disposable packaged cassette systems with commercial generators [Rheni Eo, IRE Elit, Table 1 ].
This silver chloride trapping-based 188 Re concentration system is simple, cost effective method based on the concept for post elution trapping of the macroscopic levels of the chloride anion from the saline as insoluble silver chloride in the silver-cation column. Subsequent trapping of microscopic levels of the 188 ReO 4 -1 perrhenate anion then occurs on the small QMA anion trapping column. Water washing followed by isotonic saline elution of the QMA anion column then provides highly concentrated levels of sodium 188 Re-perrhenate. This simple flow through method using inexpensive disposable components provides high specific volume solutions of 188 Re sodium perrhenate over the generator shelf-life [4] [5] .
For more cost effective extension of the useful shelf-life, the use of such effective concentration strategies is required, because of the high 188 Re bolus volumes which are obtained from generators fabricated with the relatively low specific activity 188 W. The high amounts of alumina required to bind the low specific activity 188 W parent results in high elution volumes and low specific volume solutions of 188 Re, because of the double neutron capture process and only modest thermal neutron cross section values -as compared with the very high specific activity fission-produced 188 Re concentration offers a convenient cost effective strategy for providing higher specific volume 188 Re unit doses.
Since the long useful shelf-life is an important aspect for use of this generator system, the availability of simple, efficient methods for concentration of the generator eluant is intuitively an important capability. The availability of these methods also extends the useful shelf-life of the generator since the specific volume (mCi/mL) of the generator eluate deceases as a result of the radioactive decay of the 188 Re generators can be optimized for routine clinical use by incorporating disposable tandem silver cation-chloride trapping/anion-exchange columns to provide high specific volume 188 Re solutions. The combined reproducible elution/concentration of 188 Re is rapidly conducted making routine radiopharmacy use of a concentration system practical.
Post elution concentration of the 188 Re generator eluant can have important benefits since the useful 188 W/ 188 Re generator shelf-life can be significantly extended to a few months (Figure 3) . The possible benefits of post elution eluant depend on a number of economic and technical factors. For instance, if adsorption of upfront generator cost is not a major factor and/or if patient throughout and thus reimbursement are high, then the generator can be used during a shelf-life which is limited by the 188 Re Figure 4 : Schematic illustrating the basis of the tandem silver nitrate imbedded adsorbant-based silver-chloride trapping system for subsequent anion column trapping of the 188 Re-perrhente anion for elution with low saline volume. International Journal of Nuclear Medicine Research, 2017 9 eluant specific volume (mCI/mL) required. However, other factors which may have to be considered include the high cost of generator purchase and importation and recruitment of minimal patients for 188 Re therapy. Other cost saving generator use optimization approaches which we have suggested when cost is a major factor also include the tandem connection of new generators with used generators for combined bolus collection and concentration in order to optimize the availability of 188 Re. Another important issue is the bolus saline specific volume (mCi 188 Re/mL) requirements for targeting agent radiolabeling or post elution use of 188 Re. For instance, in the case of balloon inflation with 188 Re solutions (vide infra), the specific volume must be very high (> 100 mCi 188 Re/mL), which generally would always require bolus concentration. If a large patient population can be treated with 188 Re over a short time and costs can be amortized in a short time period, than in extenso generator shelf-life and the need for post elution concentration may not be major issues. All of these factors must be evaluated and considered for each facility, but in the final analysis, it has been demonstrated by use at many radiopharmacy/clinical sites that post elution concentration of 188 Re is an effective strategy to optimize 188 W/ 188 Re generator use and cost.
Availability of Chemical Strategies for Attachment of Rhenium-188 to Targeting Agents
The evaluation of various useful Re oxidation states for radiolabeling has been evaluated and reviewed [62] [63] [64] . Because of relative stability and facile availability, Re(I) (i.e. as the tricarbonyl, Re(CO) 3 ,) [65] , Re(V) (i.e. as DEDC) and 188 Re(III)-SSS-lipiodol {SSS = (S 2 CPh)(S 3 CPh) 2 }) [63-66-67] and Re(V) (from facile reduction of Re(VII) with stannous ion, etc.) [62, 64] Re generator is similar to pertechnetate, and similar targeted agent chemical strategies can be used, and many advances have been reported. However, in comparison with the well-established and very facile and usually simple attachment of +3 Y and radioactive trivalent lanthanides to both acyclic, and especially cyclic polyamines such as DOTA, attachment of 188 Re generally requires less straight forward and more complex radiochemistry.
6.3. Availability of Preformed "Kits" for Radiopharmacy Preparation of 188 
Re-Targeting Agents
In addition to the availability of sufficiently high specific activity reactor-produced 188 W and GMP manufactured generators, another challenge has been developing/optimizing the required radiochemistry for stable attachment/introduction of 188 Re to targeting molecules. For the ease and dependable routine preparation of radiopharmaceuticals the use of sterile/pyrogen-free substrate/radiolabeling mixtures ("kits") offers many advantages for quality, dependable and easy preparation. In the context of this issue of IJNMR, several useful "kits" have been recently developed for preparation of 188 Re-labeled radiopharmaceuticals, and include kits for radiopharmacy preparation of HEDP for bone pain palliation [72] [73] [74] [75] [76] , and Lipiodol analogues (DEDC, Re-SSS) for treatment of inoperable hepatic carcinoma [77] [78] . It would be expected that further development of new "kits" will be reported if the expected expanded clinical use of other attractive 188 Re radiopharmaceuticals progresses. A major practical advantage for clinical use of 188 Re is the potential, but low, nontarget tissue toxicity of 188 Re-perrehnate, since decomposition and any release of 188 Re from the targeting molecules results in vivo re-oxidation to perrhenate, which is rapidly excreted via the urinary bladder. If necessary, either Lugol's or perchlorate can be administered for thyroid blocking. Later in this issue the details, advantages and various methods for attachment of 188 Re to radiopharmaceuticals are described in more detail.
Use of the 188 W/ 188 Re Generator System in the Radiopharmacy
One of the most efficient models would be installation of the 188 W/ 188 Re and an automated handling system in a centralized specialized facility for patient referral from local institutions. Because patient throughput for 188 Re therapy is generally limited, use of
Re generators is rarely optimized, and for this reason unit dose costs of 188 Re are generally much higher than would be expected if the generators were efficiently used in large institutions or localized for multi institutional distribution of 188 Re.
Automated Elution/Concentration Systems to Ensure Consistency of Generator Performance and Reduced Staff Radiation Exposure
The development of both in house constructed and commercially available automated systems for synthesis, purification and dispensing of radiopharmaceuticals was initially most aggressively pursued and developed for routine high yield and reproducible GMP preparation of agents radiolabeled with positronemitting radioisotopes. Recently, these systems have been more recently widely available commercially and can be readily adapted for preparation of a wide range of radiopharmaceuticals and have been demonstrated to be particularly well suited for preparation of therapeutic agents where the same issues of reproducibility, quality (GMP) and dose reduction of technical staff are key considerations. Since the 188 W product specific activity cannot be increased beyond about 10 Ci/gram W [13] [14] [15] [16] [17] [18] , as described earlier, the availability of effective and inexpensive post elution 188 Re bolus concentration methods allow a significant increase in generator useful shelf life. Use of the post elution concentration technology is well entrenched in the literature, well suited for automation and is straight forward and well established. The concentration units also require GMP manufacture and assembly and packaging. Generator and radiolabeling operation in hospital-based or for centralized radiopharmacy offers the opportunity for on demand availability of 188 Re for various therapeutic applications. Such automated systems have been described for preparation/ concentration of the 188 Re-perrhenate precursor [79] [80] [81] , 188 Re-MAG3 [82] [83] [84] [85] [86] [87] and 188 Re-Lipiodol-based agents for liver cancer therapy [88] [89] . Figure 5 illustrates a TADDEO automated system which is in use for the preparation of the 188 Re-SSS-Lipiodol agent.
Generator Manufacture under Good Manufacturing Process (GMP) Conditions
For routine use of 188 Re in the clinical arena the 188 W/ 188 Re generators must be manufactured under GMP conditions, which of course requires the availability of a sophisticated quality production facility and capabilities. Although, in addition to insuring patient safety, the generator production costs are high.
DISCUSSION
The routine commercial availability of 188 W/ 188 Re generators in Europe, India and elsewhere, is an important issue which will hopefully catalyze expanded clinical introduction of 188 Re-labeled radiopharmaceuticals in other countries. It is clear that all the "infrastructure" factors and associated required technologies are now available to offer revitalization for expanded use of 188 Re-labeled radiopharmaceuticals for routine clinical use. In addition to the attractive radionuclidic and chemical properties and relatively low and generally accepted 188 Re perrhenate radiotoxicity to non-target organs, one of the principal factors which has stimulated interest in the therapeutic applications of 188 Re is the routine, on demand availability from 188 W/ 188 Re generators available in hospital-based or centralized radiopharmacies. However, to date apparent non-optimization of generator use -as illustrated by IAEA-sponsored clinical programs with 188 Re therapy for treatment of inoperable liver cancer and for inhibition of coronary restenotic hyperplasia after PTCA -has been a recurring factor. Two key challenges which must be overcome for more cost effective clinical use of 188 Re thus include significant increase in single-and multi-institutional generator use for reduction of the resulting much higher unit dose costs, which are inconsistent taking into consideration of the long useful generator shelf-life of several months (i.e. 188 Re generator use, presumably because of the low patient trial recruitment and minimal referrals from local institutions. Since all the radiopharmacy issues for automation, 188 Re bolus concentration, quality control, etc., have been developed and are widely available, it may be expected that much greater interest in the utility and therapeutic benefits of 188 Re for targeted therapy would greatly increase if the generators were efficiently used and the unit dose costs would substantially decrease. In the opinion of this author, the most cost effective use of the 188 W/ 188 Re generator to provide 188 Re for clinical use would involve generator installation in a hospital-based or centralized radiopharmacy with the capability for 188 Re bolus concentration which would significantly extend the useful generator shelf-life and reduce 188 Re unit dose cost. From a clinical use perspective, centralized units should focus on multiple therapeutic applications of 188 Re instead of single use studies, since this would accelerate generator use. Also, to insure adequate patient throughput for therapeutic use of 188 Re, referral of patients to such a centralized site would enhance generator utilization and reduce the high costs currently encountered with use of this generator system. The advantages for clinical applications of 188 Re-labeled therapeutic agents have been recognized and are in progress in Europe and many countries in the Indian sub-continent and Asia, and hopefully this interest will expand and even be introduced into the U.S. and elsewhere.
The progress and improvements which have been made in 188 Re radiopharmaceutical development, important clinical applications in nuclear medicine and oncology, automation and bolus concentration would be expected to re-stimulate production, distribution and use of the 188 W/ 188 Re generator. While 4-5 institutions/ commercial entities had produced and distributed these generators several years ago, apparently only 2-3 manufacturers now provide the 188 W/ 188 Re generators ( Table 1) . As well established in both the radiopharmaceutical and clinical literature, although 188 Re has excellent radionuclidic properties and routine availability from a long shelf life generator, the cost and availability of the 188 W/ 188 Re generators are two issues which have apparently limited the expected further widespread clinical introduction of 188 Re. In addition, one may argue that another issue associated with the under-utilization of 188 Re may be the chemical challenges for facile introduction of 188 Re into 188 Retargeting molecules. The transition metal chemistry of NCA perrhenate is similar to the well described chemistry for pertechnetate [62] [63] [64] , but there are distinct differences, which include the requirement for stronger reducing conditions for the conversion of perrhenate [Re(VII)] to Re(V). In addition, care that must be taken to avoid re-oxidation of Re(V) by the use of inert conditions and often by introduction of various antioxidant agents during the radiolabeling procedures (gentissic acid, etc.). Chemical attachment of 188 Re in comparison with other therapeutic radionuclides, moreover, requires reaction conditions which are much more facile for radiolabeling acyclic chelators and cyclic multi-dentate chelators such as DOTA with trivalent M +3 metals, for instance, such as 177 Lu [91] . Radiolabeling with 177 Lu generally involves simple combination of the radioisotope and chelator solutions with perhaps some heating which is sufficient for high yield formation of the desired targeting agents. These techniques are much easier, facile and straight forward than the general radiolabeling conditions required for introduction of 188 Re into radiopharmaceuticals. Although 188 Re may represent in some sense a "poor man's 90 Y" [91] , from many perspectives use of 188 Re has many advantages in comparison to the use of 90 Re generators would be expected to be readily expanded, the major challenges for broader routine reimbursed clinical use of 188 Re-labeled radiopharmaceuticals will of course now be dependent on major investments required for development, regulatory approval and introduction of new 188 Re-labeled therapeutic agents.
CONCLUSIONS
In spite of these challenges, interest in the use of 188 Re continues on an international basis and continued important advances are being reported for 188 Re radiopharmaceutical targeting strategies and for substrate radiolabeling. These advances and important descriptions of the excellent clinical outcomes using 188 Re-labeled radiopharmaceuticals for liver cancer therapy, bone pain palliation and other therapeutic applications are described in this issue of the International Journal of Nuclear Medicine and Research, and underline the importance of continuation of studies focused on the development and evaluation of 188 Re-labeled agents.
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